Trinity Biotech (TRIB) Other Accumulated Expenses (2009 - 2024)

Trinity Biotech has reported Other Accumulated Expenses for 16 years, with the latest figure at $3.0 million in Q4 2024.

• Quarterly Other Accumulated Expenses rose 4.15% year-over-year to $3.0 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $3.0 million (up 4.15% YoY) and the FY2024 annual result came in at $3.0 million, up 4.15% from the prior year.
• Other Accumulated Expenses rose to $3.0 million in Q4 2024 per TRIB's latest filing, from $1.8 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $69.3 million in Q4 2020 and troughed at $1.8 million in Q1 2024.
• A 5-year average of $17.0 million and a median of $13.0 million in 2022 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2020 and 2024: Other Accumulated Expenses gained 7.87% in 2020, then slumped 83.54% in 2024.
• Over 5 years, Other Accumulated Expenses stood at $69.3 million in 2020, then fell by 0.79% to $68.8 million in 2021, then slumped by 82.16% to $12.3 million in 2022, then tumbled by 76.61% to $2.9 million in 2023, then climbed by 4.15% to $3.0 million in 2024.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $3.0 million, $1.8 million, and $1.8 million for Q4 2024, Q3 2024, and Q2 2024 respectively.